Navigation Links
DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments
Date:8/29/2014

previous glioblastoma clinical trials conducted by the National Cancer Institutes in the United States. The Company believes that such higher doses may enhance the potential of VAL-083 to impact a patent's tumor and improve patient outcomes. Ultimately, DelMar believes advancing to higher doses will increase the chance of success in achieving the longer-term goal to commercialize VAL-083 as a new chemotherapy for glioblastoma patients who have failed, or are unlikely to respond, to currently available treatments.
  • DelMar presented new non-clinical research supporting the potential utility of VAL-083 in the treatment of non-small cell lung cancer at AACR in April.
  • DelMar received an additional CDN $194,000 nonrefundable funding contribution from that National Research Council of Canada (NRC). Four non-dilutive funding contributions to date from NRC total CDN $327,000 and will be used to support continued non-clinical research aimed at providing competitive differentiation for VAL-083 as a new medicine in the treatment of glioblastoma and other cancers, including non-small cell lung cancer.
  • DelMar received gross proceeds of $2,373,937 from the exercise of warrants at $0.65 per warrant that closed on June 6 and an additional $495,448 in gross proceeds from exercise of these warrants under the tender offer which closed on August 8. The exercise of warrants through a private transaction with certain warrant holders and subsequent tender offer has provided the Company with additional non-dilutive capital, which the Company believes will be sufficient to fund current operations through at least the end of December 2015. 
  • Jeffrey Bacha, president & CEO of DelMar Pharmaceuticals stated, "We are pleased with the overall progress made during the past year in research and development activities. The warrant tender offer and change in our fiscal year end are part of our ove
    '/>"/>

    SOURCE DelMar Pharmaceuticals, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
    2. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
    3. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
    4. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
    5. DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
    6. DelMar Pharmaceuticals to Present at the 25th Annual ROTH Capital Partners Growth Stock Conference
    7. DelMar Pharma Named to Rocket Builders 2013"Ready to Rocket" List
    8. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
    9. DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
    10. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
    11. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2015)... CHICAGO , July 31, 2015 ... Pipeline Review, 2015 market research report that provides ... pipeline stage using data sourced from in-house databases, ... on syringes and needles market products pipeline spread ... organizations supported with 73 tables and 5 figures ...
    (Date:7/31/2015)... , July 31, 2015 Quietly, ... of experience, the domestic pharmaceutical industry is strong, with ... products to high international standards. One place ... is in sub-Saharan Africa: Morocco has quietly become the ... South Africa . Indeed, Moroccan pharma companies ...
    (Date:7/31/2015)... CHICAGO , July 31, 2015 ... Composition Analyzers Market by Product (Bioimpedance Analyzers (BIA), Dual-Energy ... and Hydrostatic Weighing) - Global Analysis & Forecast to ... Market was pegged at $911.1 Million 2014 and is ... at a CAGR of 9.4% from 2014 to 2019. ...
    Breaking Medicine Technology:Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5PharmaBoardroom Releases New Morocco Pharmaceuticals Report 2PharmaBoardroom Releases New Morocco Pharmaceuticals Report 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4
    ... CV Therapeutics, Inc.,(Nasdaq: CVTX ) announced today ... Cardiology 57th Annual Scientific Session in Chicago,showed that ... isolated from animals and humans., The Company ... ranolazine may,contribute to the statistically significant reductions in ...
    ... PAREXEL International,Corporation (Nasdaq: PRXL ), a ... Company had completed the expansion of,three Clinical Pharmacology ... States; London, United Kingdom; and Berlin, Germany in ... in the early,phases of clinical development., "Continued ...
    Cached Medicine Technology:New Data Shows Ranexa(R) Increases Glucose-Stimulated Insulin Secretion 2New Data Shows Ranexa(R) Increases Glucose-Stimulated Insulin Secretion 3PAREXEL Expands Global Clinical Pharmacology Capabilities 2PAREXEL Expands Global Clinical Pharmacology Capabilities 3PAREXEL Expands Global Clinical Pharmacology Capabilities 4PAREXEL Expands Global Clinical Pharmacology Capabilities 5
    (Date:8/1/2015)... ... August 01, 2015 , ... BeverlyD, owner and founder of BeverlyD Luxe ... the very first small business donation to kick off the campaign for healing and ... Her legacy includes a complete line of raw, organic hair care products, as well ...
    (Date:7/31/2015)... ... 2015 , ... Ticket Down is a reputable source of authentic tickets for the 2015 ... Fans of every genre of music will have an act they are excited to see ... festival, the following artists will perform: Sam Smith, Coldplay, Kenny Chesney, The Who, Jason ...
    (Date:7/31/2015)... ... ... Ticket Down is a reliable source for authentic tickets for the 2015 ... festival will end on Sunday, August 2nd. , Music fans have traveled ... unique and unbelievably popular festival attracts the best in entertainment from around the world. ...
    (Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... The 2nd ... Church Park in Downtown Memphis on October 3, 2015. The Ride to Fight On ... on cancer research between Methodist Healthcare, The West Clinic and The University of Tennessee ...
    (Date:7/31/2015)... ... July 31, 2015 , ... ... Insurance Group, Inc. has re-branded their social media profiles to better connect with ... for consumers to communicate, find information, share insights and opinions. The Rally Insurance ...
    Breaking Medicine News(10 mins):Health News:March4thforWellBeing Foundation Kickoff 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 3Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2
    ... risk in teens, study suggests , TUESDAY, Dec. 15 ... increases the risk of obstructive sleep apnea, but the ... children, Australian researchers have found. , In sleep tests ... who were referred for evaluation of snoring and possible ...
    ... RPS Worldwide ... income... known as one of the simplest and easiest business opportunities in America today. ... Orlando, FL (PRWEB) December 15, ... cheer and good will that is going to stick around long after the season,s end. ...
    ... examines potential for injury when doctors decide benefits of ... News) -- MRI scans can pose a serious risk ... Food and Drug Administration researchers exposed pacemakers to a ... voltage produced at the tip of the pacemaker lead, ...
    ... nearly as accurate a surgical method, with fewer complications, ... When it comes to diagnosing breast cancer, women and ... that the less invasive "core needle biopsy" procedure is ... open surgical procedure is, with fewer complications than the ...
    ... , , NEW YORK, ... market research report is available in its catalogue: ... the U.S. and its International Trade [Q4 2009 ... newly published In-Vitro Diagnostic Substance Manufacturing Industry report ...
    ... ... R.I., Dec. 15 Mergers and acquisitions are commonplace today. As competitors ... they also must face integration challenges, including the integration of safety programs. ... Practices in a Hearing Conservation Program: US Airways ," details how the ...
    Cached Medicine News:Health News:Puberty May Trigger Sleep Apnea in Overweight Kids 2Health News:RPS Worldwide Launches Affiliate Program -- The Collection Agency That Gives Christmas Back, Rather Than Take it Away 2Health News:RPS Worldwide Launches Affiliate Program -- The Collection Agency That Gives Christmas Back, Rather Than Take it Away 3Health News:Patients With Pacemakers Should Avoid MRI Scans 2Health News:Needle Biopsy Works Well in Diagnosing Breast Cancer 2Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 2Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 3Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 4Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 5Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 6Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 7Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 8Health News:New White Paper Details Best Practices of an Occupational Hearing Conservation Program: US Airways 2Health News:New White Paper Details Best Practices of an Occupational Hearing Conservation Program: US Airways 3Health News:New White Paper Details Best Practices of an Occupational Hearing Conservation Program: US Airways 4
    Urethral Red Rubber Catheters (Latex)...
    Coude Foley Catheters (Latex) 2-Way Red...
    Silicone Elastomer-Coated Latex Foley Catheters 3-Way...
    Midstream Catch Kits...
    Medicine Products: